secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001654954-26-002928
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience to voluntarily deregister, cease SEC reporting; CFO and director resign
--------------------------------------------------------------------------------

- CFO William Sullivan resigns effective March 30, 2026; board member Alison Cornell resigns immediately as part of cost-cutting measures.
- Company expects to file Form 15 on March 30, 2026 to suspend SEC reporting obligations and delist from OTC markets.
- CEO letter states anticipated revenue from AgTech distribution partner in coming months, targeting first-time positive cash flow.
- Board compensation eliminated; CEO continues to invest personal capital; alignment with shareholders emphasized.
- University of Georgia granted funds to study Zivo's product for Avian Influenza using company's algal immune-modulating technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495426002928/0001654954-26-002928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495426002928/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-26-002928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer